Modelling Decay of Population Immunity With Proposed Second Dose Deferral Strategy
Jurgens, G. T.
Show abstract
A second dose deferred strategy has been proposed to increase initial population immunity as an alternative to the default two dose vaccine regimen with spacing of 21 or 28 days between vaccine doses for the mRNA vaccines from Pfizer and Moderna. This increased initial population immunity is only of value if one dose immunity does not decay so fast as to nullify the benefit. Because decay rates of one dose and two dose efficacy are currently unknown, a model to project population immunity between the two strategies was created. By evaluating the decay rate of one dose efficacy, two dose efficacy, and time until the second dose is given, the model shows that if there is an increased decay rate of one dose efficacy relative to the two dose decay rate, it is highly unlikely to nullify the benefit of increased population immunity seen in a second dose deferral strategy. Rather, all reasonable scenarios strongly favour a second dose deferral strategy with much higher projected population immunity in comparison to the default regimen.
Matching journals
The top 2 journals account for 50% of the predicted probability mass.
Similar papers in this journal
Similar papers in this journal
- Evaluating the effects of vaccine rollout policies in European countries: A simulation study 94%
- Estimating the number of symptomatic SARS-CoV-2 infections among vaccinated individuals in the United States—January–April, 2021 93%
- Beyond the new normal: assessing the feasibility of vaccine-based elimination of SARS-CoV-2 93%
Similar papers in this journal
- Analysis of host immunological response of adenovirus-based COVID-19 vaccines 94%
- Fall 2021 Resurgence and COVID-19 Seroprevalence in Canada Modelling waning and boosting COVID-19 immunity in Canada A Canadian Immunization Research Network Study 94%
- Cost-effectiveness of quadrivalent versus trivalent inactivated influenza vaccines for the Portuguese elderly population 94%
Similar papers in this journal
- Predictors for Reactogenicity and Humoral Immunity to SARS-CoV-2 Following Infection and mRNA Vaccination: A Regularized Mixed-Effects Modelling Approach 93%
- Safety and Immunogenicity of Intradermal Administration of Fractional Dose CoronaVac ® , ChAdOx1 nCoV-19 and BNT162b2 as Primary Series Vaccination 92%
- Safety and immunogenicity of GamEvac-Combi, a heterologous rVSV- and rAd5-vectored Ebola vaccine: a randomized controlled multicenter clinical trial in the Republic of Guinea and Russia 92%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.